Senolytics are agents being studied for their ability to selectively eliminate certain senescent cells. They are a research strategy, not a single ingredient or a guarantee of rejuvenation. Different senescent-cell states may respond differently, so selectivity is central to the concept.

Why scientists are interested

Persistent senescent cells can influence surrounding tissues through their secreted signals. Researchers have therefore asked whether removing particular populations could improve disease-related function. The hypothesis is more specific than “remove old cells”: the target, tissue, timing and consequences all matter.

An early open-label study of dasatinib plus quercetin in people with idiopathic pulmonary fibrosis investigated feasibility and physical-function signals. Because it lacked a control group, it could not establish that any observed change was caused by the treatment. Justice and colleagues, 2019

A subsequent small randomized, placebo-controlled pilot focused on feasibility and tolerability. A pilot designed for those questions should not be presented as proof of longevity benefit or general clinical effectiveness. Nambiar and colleagues, 2023

What remains to be established

A useful treatment would need to improve a meaningful outcome in a defined population, with harms assessed over an appropriate period. Eliminating cells can have unintended effects, and compounds studied as senolytics may have other biological actions. Results in one disease cannot be generalized automatically to healthy aging.

Reading claims responsibly

Ask whether the study measured cell markers, symptoms, function, disease progression or survival. Those endpoints are not interchangeable. Also check whether the tested formulation matches the product being promoted.

Senolytics are an active area of research, but the word itself does not establish safety, efficacy, approval or suitability for personal use. This article is an explanation of the strategy, not a regimen.